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ABSTRACT
This study investigated the analgesic effects of a THC pro-drug in a rodent model of recurrent migraine.
Rats received 4 nitroglycerin-induced (NTG: 10mg/kg/2ml) migraine episodes every third day for 12 days; saline,
cremaphor-vehicle, propranolol (10mg/kg/ml), or THC-VAL-HS (0.5, 1.0, and 2.0 mg/kg/ml) were given IP 30
minutes before NTG. Behavioral endpoints of photosensitivity, activity, orbital tightening, and tactile allodynia
were assessed 110 m after NTG. Migraine severity increased over the course of the four episodes, pointing
toward chronification and an important step in model validation. However, neither propranolol nor THC-VAL-HS
significantly attenuated any of the migraine-related endpoints. These data are in contrast with clinical reports
that marijuana mitigates migraine severity. These findings suggest that higher doses of THC-VAL-HS and/or
other cannabinoid constituents in marijuana may be responsible for such anecdotal anti-migraine activity of
cannabis.

INTRODUCTION & BACKGROUND
As migraine research has progressed,
the translational relevance of available
models has improved. The first generation
of models sought to determine the effects
of administered nitroglycerine (NTG) in
rats on the outcome of some potentially
relevant clinical endpoints (Tassorelli et al.
2003). In preliminary studies, rats were
administered NTG and tested for signs of
hyperalgesia, largely through the tail flick
apparatus.
This
experiment
found
significant increases in hyperalgesia at 2
and 4 hours post-NTG injection. These
results validated a clinically relevant
induction of migrane and revealed the
possible role of nitrovasodilators in pain

modulation. Though this experimental
format may have had its merits, it lacked
translational relevance to the clinical
picture. The clinical need focuses on
episodic migraine, which is characterized
by
recurrent
migraine
episodes.
Additionally, the endpoints measured in
this current model of migraine are not
diagnostic criteria for migraine in the
clinical picture.
In the second generation of migraine
modelling,
translational
relevance
improved by relying on multiple NTG
administrations and migraine inductions
(Pradhan et al. 2013). In this experiment,
mice were injected with NTG every other
day for 9 days, resulting in 5 total NTG

injections.
This
experiment
found
significant increases in hyperalgesia related
to von Frey mechanical sensitivity
(technically these endpoints measured
allodynia), and that these effects not only
persisted, but worsened with episodic
migraine induction. The implementation of
recurrent NTG administration helped to
improve the translational relevance of this
migraine model, in regards to frequency,
though they still neglected more clinically
relevant endpoints of episodic migraine by
focusing solely on hyperalgesia.
The third generation of migraine
models sought to include more relevant
diagnostic endpoints in its assessment of
episodic migraine (Sufka et al. 2016). This
experiment subjected rats to 5 NTG
injections over the course of 15 days and
measured the effect on the novel
endpoints of expressed facial pain (using
the Rat Grimace scale) and photophobia
and decreased movement (both quantified
using a Light/Dark box). The results of this
experiment showed a significant decrease
in locomotor activity and an increase in
light sensitivity over the course of the five
test sessions. These changes helped to
further refine the model and aid in
producing a more clinically relevant
representation of the chronic migraine
episodes necessary for a clinical diagnosis
of episodic migraine.
The final generation of modelling, and
the one that is utilized in this experiment,
sought to add an additional clinically
relevant endpoint representative of tactile
allodynia (Harris et al. 2017). This
experiment
followed
the
recurrent

administration of NTG that previous
models utilized, but added a new
apparatus in an attempt to quantify the
development
of
tactile
allodynia
associated with chronification of migraine.
This new apparatus is a circular arena
consisting of two half fields of sandpaper
of differing grit and seeks to quantify
movement data as well as preference for
one half field or the other. Through the
implementation of this new apparatus, a
significant increase in tactile allodynia, as
measured by a decrease in movement and
a preference for spending time on the
smoother sandpaper, was recorded during
the course of this experiment. However,
this increase only occurred during the 5th
episode, which indicates that tactile
allodynia may be a more accurate indicator
of the chronification of migraine.
Additionally,
anecdotal
evidence
points to the possible efficacy of cannabis
in alleviating symptoms of migraine. As
early as the year 700 B.C.E., Indian
ayurvedic medicine touted the ability of
cannabis to be utilized for migraine pain
(Russo, 1998). These anecdotal reports
continued and persist even to this day,
attesting to the possible benefits of
cannabis use for migraine treatment
(Russo, 1998).
However, reports of the analgesic
properties of cannabis extend beyond
anecdotal evidence and have been
experimentally tested as well. A 1972
study sought to compare the analgesic
properties of THC to those of morphine
(Buxbaum, 1972). To accomplish this goal,
rats were administered intraperitoneal

injections of THC or morphine and then
subjected to hot plate and tail flick tests.
This
experiment
found
that
an
intraperitoneal injection of THC had
analgesic effects equipotent to morphine
in rats.
Furthermore, the analgesic effects of
THC have also been demonstrated in
human trials (Noyes Jr et al. 1975). Patients
suffering from continuous pain attributed
to cancer were administered varying doses
of THC, and had their pain relief compared
to the effects of codeine. This experiment
found that a 20 mg dose of THC was
slightly more effective at relief and
reduction of pain than a 120 mg dose of
codeine. This experiment speaks to the
analgesic properties of THC and provides
some validity for anecdotal efficacy in
humans.
Thus, using both the recurrent
migraine protocol with its clinically relevant

endpoints and the evidence of THC’s
efficacy as an analgesic, this study utilized
a THC pro-drug formulation in the
recurrent migraine model in rats .
MATERIAL & METHODS
Rats received 4 NTG migraine episodes
every third day over a 12 day period.
Nitroglycerin
(10
mg/kg/2mL)
was
administered IP 30 minutes after IP
injections of either saline, cremaphorvehicle, 20 mg/kg/mL propranolol or THC
(0.5, 1.0, or 2.0 kg/mg/mL). Orbital
tightening was captured 30 minutes post
nitroglycerin administration. Behavioral
endpoints were assessed 110 minutes post
nitroglycerin administration and included
measures of photophobia and activity in
the light/dark box and spontaneous tactile
allodynia in an arena. Sample sizes were n
=.5-10.

RESULTS

FIGURE 1. Weight Data- In general, weight increased for all test groups across all test
sessions. On the day following a migraine episode, weight decreased among all groups. A

significance was found for Day but there was no significant effect for Treatment and no
significant Day x Treatment interaction.

FIGURE 2. Orbital Tightening- Orbital tightening measures were collected 30 minutes post
nitroglycerin administration. No systematic pattern showing changes or worsening of orbital
tightening nor any separation among treatment groups in a consistent manner was detected
from these data. No significant effect was found for Day or Treatment and there was no
significant Day x Treatment interaction.

FIGURE 3. Movement data in L/D Box- Mean movement data was collected 110 minutes postNTG administration. Movement generally decreased for all treatment groups across all test
sessions. There was found to be a significant effect for Day, but no significant effect for
Treatment and no significant Day x Treatment interaction.

FIGURE 4. Photosensitivity in L/D Box- Time spent in light was quantified 110 minutes postNTG administration. Time spent in light generally decreased for all treatment groups across
all test sessions. There was found to be a significant effect for Day, but no significant effect for
Treatment and no significant Day x Treatment interaction.

FIGURE 5. Movement Data in Open Arena- Mean movement data was collected 110 minutes
post-NTG administration. Movement generally decreased for all treatment groups across all
test sessions. A significant effect was found for Day, but there was no significant effect for
Treatment and no significant Day x Treatment interaction.

FIGURE 6. Time Spent in Half Field- Time spent on the 40-grit half of the open tactile arena
was quantified 110 min post-NTG administration. There was a significant effect for Day, but
no significant effect for Treatment and no significant Day x Treatment interaction.
DISCUSSION
This experiment suffers from some
limitations and has some opportunities to
improve. First, orbital tightening is
presented as an early indicator of
photosensitivity, yet this measure is not
temporally connected to measures of
photosensitivity in the light-dark box. This
experiment would benefit from having
these two endpoints more closely linked,
perhaps by removing subjects from the
light-dark box to assess orbital tightening
scores.
Second,
data
about
weight
progression and its relation to migraineinduced nausea over the course of the
recurrent migraine protocol is tenuous.
Thus, we can only infer that these changes
in weight data are related to migraineinduced nausea simply because it appears

to mirror the clinical presentation of
migraine. Evidence that body weight
changes in this “staircase” design may be
a surrogate measure for nausea could be
obtained from an experiment that utilized
a compound that was known to induce
nausea in animals.
Third,
the
novel
measure
of
spontaneous tactile allodynia in the open
arena could benefit from validation
through additional studies. It would be
beneficial to determine if this arena
apparatus generalizes to other models that
present spontaneous allodynia, such as a
cisplatin-induced
neuropathy
model
(Authier et al. 2000). If spontaneous
allodynia in other models can be measured
by movement in the arena apparatus, the
next step would be to determine whether
spontaneous allodynia differs from evoked
allodynia in pharmacological sensitivity.

Finally, the absence of a prophylactic
agent in attenuating these migraine
endpoints is a limitation in regards to drug
screening. Model validity could be greatly
improved
with
an
increase
in
pharmacological sensitivity. Efficacious and
non-efficacious migraine therapies should
screen positive and negative in the model,

respectively, while also avoiding false
positives and false negatives.

CONCLUSION

session. These data are in contrast with
clinical reports that marijuana mitigates
migraine severity. These findings suggest
that higher doses of THC-VAL-HS and/or
other
cannabinoid
constituents
in
marijuana may be responsible for such
anecdotal
anti-migraine
activity
of
cannabis.

The current model of episodic migraine
appears to accurately model chronification,
though some of its paradigms could use
validation with other measures. Neither
propranolol nor THC-Val-HS attenuated any of
the migraine endpoints on any test
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